Clinical trials: Infection Risk
Human Immunodeficiency Virus Exposure, Alcohol; Harmful Use
Game Plan for PrEP
This small pilot randomized controlled trial will test whether a brief, web-based intervention inspired by the principles of motivational interviewing helps high-risk men who take pre-exposure prophylaxis (PrEP) moderate their…
- Trial name
- NCT04973267
- Testing
- Game Plan for PrEP, Attention-Matched Control Lifestyle Habits Videos
- Where
- United States
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- Brown University
RSV Infection
A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications.
This was a Phase 2b, randomized, double-blind, placebo-controlled study of EDP-938 administered orally for the treatment of non-hospitalized adult subjects with confirmed RSV infection who were at high risk for complications…
- Trial name
- RSVHR (NCT05568706)
- Testing
- EDP-938
- Where
- 84 sites in United States, Argentina and 10 more
- Volunteers
- 187 people
- Sponsor
- Enanta Pharmaceuticals, Inc
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer
RATIONALE: Growth factors, such as palifermin, may prevent chronic graft-versus-host disease caused by donor stem cell transplant.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Trial name
- NCT01233921
- Testing
- palifermin, flow cytometry, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Martin, Paul
HIV-1-infection, COVID-19
HIV-1 & Coronavirus-Coinfection in Europe: Morbidity & Risk Factors of COVID-19 in People Living With HIV
HIV CoCo is a European multi-centre, multi-country, retrospective, observational case-control study that will aim to describe clinical outcomes and identify risk factors for People Living With HIV (PLWHIV) who are co-infected…
- Trial name
- HIV CoCo (NCT05481216)
- Testing
- COVID-19, HIV-1 infection
- Where
- 23 sites in Belgium, France and 3 more
- Volunteers
- 2,598 people
- Sponsor
- NEAT ID Foundation
Coronavirus
COVID-19 Risk Reduction Among African American Parishioners
African American adults, specifically those managing chronic disease and social isolation, are one of the most vulnerable groups susceptible to COVID-19.
- Trial name
- NCT04542343
- Testing
- Change in knowledge, motivation, skills, resources
- Where
- United States
- Volunteers
- 405 people, healthy volunteers welcome
- Sponsor
- Charles Drew University of Medicine and Science
Healthy Participants
COVID-19 Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoclonal Antibodies for Prevention of SARS CoV-2 Infection Asymptomatic in Healthy Adults and Adolescents Who Are Household Contacts to an Individual With a Positive SARS-CoV-2 RT-PCR Assay
Primary Objectives: Cohort A: To evaluate the efficacy of REGN10933+REGN10987 compared to placebo in preventing symptomatic SARS-CoV-2 infection (broad-term) confirmed by RT-qPCR Cohort A and Cohort A1: To evaluate the safety and…
- Trial name
- NCT04452318
- Testing
- REGN10933 + REGN10987
- Where
- 134 sites in United States, Moldova and 1 more
- Volunteers
- 3,303 people, healthy volunteers welcome
- Sponsor
- Regeneron Pharmaceuticals
COVID-19
ABX464 in Treating Inflammation and Preventing Acute Respiratory Failure in Patients With COVID-19
A phase 2/3, randomized, double blind, placebo-controlled study to evaluate the efficacy and the safety of ABX464 in treating inflammation and preventing acute respiratory failure in patients aged ≥65 and patients aged ≥18 with…
- Trial name
- Mir-Age (NCT04393038)
- Testing
- ABX464
- Where
- 30 sites in Belgium, Brazil and 6 more
- Volunteers
- 509 people
- Sponsor
- Abivax S.A.
Respiratory Syncytial Virus
A Study of Rilematovir (JNJ-53718678) in Adult Outpatients With Respiratory Syncytial Virus (RSV) Infection
The purpose of this study is to evaluate the efficacy of rilematovir compared to placebo with respect to the time to resolution of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) symptoms.
- Trial name
- PRIMROSE (NCT04978337)
- Testing
- Rilematovir
- Where
- 86 sites in United States, Argentina and 12 more
- Volunteers
- 5 people
- Sponsor
- Janssen Research & Development, LLC
Respiratory Syncytial Virus Infections
Prospective Study for the Use of Palivizumab (Synagis®) in High-risk Children in Germany
The SYNAGIS Registry was carried out in order to gather comprehensive real-world data on the use of palivizumab in children at high risk for serious respiratory syncytial virus (RSV) disease.
- Trial name
- NCT01155193
- Volunteers
- 30,804 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
COVID-19
A Study to Evaluate EDP-235 in Non-hospitalized Adults With COVID-19
Study of EDP-235 in Non-hospitalized Adults with Mild or Moderate COVID-19.
- Trial name
- SPRINT (NCT05616728)
- Testing
- EDP-235
- Where
- 23 sites in United States, Romania
- Volunteers
- 231 people
- Sponsor
- Enanta Pharmaceuticals, Inc
Fungal Infections
Pharmacokinetics and Safety of Posaconazole Tablet in Participants at High Risk for Invasive Fungal Infections (MK-5592-065/P05615)
The purpose of this study is to collect pharmacokinetic (PK) information related to how well posaconazole tablet is distributed in the body and to determine the safety of this new formulation.
- Trial name
- NCT01777763
- Testing
- Posaconazole 200 mg, Posaconazole 300 mg
- Volunteers
- 230 people
- Sponsor
- Merck Sharp & Dohme LLC
Respiratory Syncytial Virus Infections
A Study on the Immune Response and Safety of an RSV Vaccine When Given to Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant and Are at an Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease and Compared to Healthy Adults 50 Years of Age and Above
The purpose of this study is to evaluate the immunogenicity, safety, and reactogenicity of the RSVPreF3 OA investigational vaccine in an immunocompromised (lung and renal transplant recipients) population and assess whether a…
- Trial name
- RSV OA=ADJ-023 (NCT05921903)
- Testing
- RSVPreF3 OA Investigational Vaccine
- Where
- 46 sites in United States, Australia and 6 more
- Volunteers
- 386 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Monkeypox, HIV Coinfection
Morbidity, Mortality And Risk Factors of Mpox in HIV Negative High Risk Sexual Health Clinic Attenders and People Living With HIV
This data collection study aims to describe and compare the outcomes of Mpox on people living with HIV (PLHIV) and HIV-negative individuals who are on pre-exposure prophylaxis (PrEP).
- Trial name
- MASH1 (NCT05965427)
- Testing
- No intervention
- Where
- 9 sites in France, Poland and 2 more
- Volunteers
- 2,000 people
- Sponsor
- NEAT ID Foundation
Human Immunodeficiency Virus 1
A Study to Compare Brachial Artery Reactivity and Cardiovascular Risk of a Treatment Simplification by Darunavir/Ritonavir (DRV/r) 800/100 mg Versus a Triple Combination Therapy Containing DRV/r in HIV-1 Infected Patients
The purpose of this study is to compare change of brachial artery flow mediated vasodilatation using Darunavir/Ritonavir (DRV/r) 800/100 mg once daily as a monotherapy (use of a single medication) versus a triple combination…
- Trial name
- MONARCH (NCT01391013)
- Testing
- Darunavir(DRV), Ritonavir, 2 nucleoside reverse transcriptase inhibitors (NRTIs)
- Volunteers
- 30 people
- Sponsor
- Janssen-Cilag S.p.A.
HIV Infections
Improving Treatment and Retention Adherence in Nontraditional Settings
This is a hybrid implementation-effectiveness study using both qualitative and quantitative methods. The research aims to examine whether providing a new, but approved, HIV once a month injection treatment…
- Trial name
- I-TRAINS (NCT04973254)
- Testing
- CAB-RPV LA, Standard treatment within an HIV clinic
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Boston Medical Center
Pneumococcal Disease
A Phase III Clinical Trial to Study the Safety and Immunogenicity of Pneumovax™ 23 (V110) in Participants From the Russian Population (V110-018)
The purpose of this study is to determine if Pneumovax™ 23 (V110) is safe and immunogenic in participants from the Russian population who are 50 years of age and older or 2 to 49 years of age and at increased risk for…
- Trial name
- NCT01734239
- Testing
- Pneumovax™ 23
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Human Immunodeficiency Virus, Cardiometabolic Risk
The Happy Older Latinos Are Active (HOLA) Health Promotion Study in HIV-Infected Latino Men
The purpose of this study is to examine the feasibility of an intervention to prevent chronic diseases like diabetes, high blood pressure, and obesity in midlife and older Latino adults living with HIV.
- Trial name
- HOLAHIV (NCT03839212)
- Testing
- HOLA Component 1, HOLA Component 2, HOLA Component 3
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of Miami
Fungal Infection
Pharmacokinetics and Safety of Intravenous Posaconazole (MK-5592) in Chinese Participants at High Risk for Invasive Fungal Infections (MK-5592-120)
The purpose of this study is to evaluate the pharmacokinetics and safety of posaconazole intravenous solution in Chinese participants at high risk for invasive fungal infections.
- Trial name
- NCT03336502
- Testing
- Posaconazole
- Where
- 7 sites in China
- Volunteers
- 70 people
- Sponsor
- Merck Sharp & Dohme LLC
Cancer
Maintain Respiratory Muscle Function and Reduce Pneumonia Risk in Cancer Patients
This research is intended to begin to explore the impact of inspiratory muscle resistance exercise and/or 1,25(OH)2D3 for improving respiratory muscle strength in cancer patients (subjects).
- Trial name
- NCT03469271
- Testing
- 1,25 (OH)2 D3, Inspiratory isometric resistance training, Threshold Inspiratory Muscle Trainer (IMT)
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Mayo Clinic
Rabies
Comparison of SYN023 to Human Rabies Immune Globulin in Post Exposure Prophylaxis of Rabies
This is a Phase 2b, double blinded, randomized study of SYN023 compared to HyperRab® (a licensed Rabies immune globulin from human sources, HRIG) for the prevention of rabies as part of post-exposure prophylaxis (PEP).
- Trial name
- ARPEP (NCT03961555)
- Testing
- SYN023, HRIG (HyperRab), Rabies vaccine
- Where
- 14 sites in United States, Philippines
- Volunteers
- 448 people
- Sponsor
- Synermore Biologics Co., Ltd.